Novartis | NVS - Interest Expense On Debt


Novartis reported $281M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Amgen USD 653M 94.99B Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Bausch Health Companies USD 398M 2M Sep/2026
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 403M 4M Sep/2026
Canopy Growth CAD 12.68M 364K Jun/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 316M 201.3M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Glaxosmithkline GBP 264.74M 72.01M Sep/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Novartis USD 281M 8M Sep/2025
Pacira USD 112.4M 108.78M Sep/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 662M 5M Sep/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 13.94M 2.52M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Sanofi EUR -25M 99.78M Dec/2025
Supernus Pharmaceuticals USD 718K 1.6M Sep/2026
Zoetis USD 62M 1000K Sep/2026